

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA: Lumacaftor and ivacaftor combination therapy for treating cystic fibrosis homozygous for the F508del mutation**

**Batch 42**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues have been identified.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Not applicable.

**Approved by Associate Director (name):** Helen Knight

**Date:** 11/09/2015